个体化fMRI功能连接定义重性抑郁障碍抗抑郁药与安慰剂应答特征
基于EMBARC研究中296例重性抑郁障碍患者随机接受舍曲林或安慰剂双盲治疗8周的数据,利用治疗前静息态fMRI构建全脑功能连接网络,并通过去除共同成分实现个体化功能连接。个体化功能连接预测模型分别解释舍曲林组HAMD17变化22%方差和安慰剂组31%方差,预测性能显著优于原始功能连接模型,且两组预测性连接指标脑区分布不同。
要点
- 个体化功能连接预测舍曲林组HAMD17变化解释22%方差,安慰剂组31%方差。
- 个体化功能连接模型预测性能显著优于原始功能连接模型,并经交叉验证确认。
- 舍曲林预测指标主要位于左侧颞中回和右侧岛叶,安慰剂主要位于双侧扣带回和左侧颞上回。
核心结论
- 去除共同功能连接成分实现个体化后,功能连接指标对舍曲林和安慰剂治疗应答的预测性能均显著提升。
研究设计与样本
- 数据来自EMBARC研究,296例重性抑郁障碍患者随机分配至舍曲林或安慰剂双盲治疗8周。
- 基于治疗前静息态fMRI构建全脑功能连接网络,去除原始基线功能连接中提取的共同成分以实现个体化,训练基于回归的连接预测模型。
主要发现
- 个体化功能连接特征建立的预测模型解释舍曲林组HAMD17变化22%方差,安慰剂组31%方差。
- 与基于原始功能连接的模型相比,个体化功能连接定义的特征显著改善预测性能,并经交叉验证确认。
- 舍曲林治疗预测性功能连接指标主要位于左侧颞中回皮层和右侧岛叶。
- 安慰剂预测性功能连接指标主要位于双侧扣带回皮层和左侧颞上回皮层。
临床怎么用
- 个体化功能连接指标可能有助于区分重性抑郁障碍患者对舍曲林与安慰剂的应答特征,为个性化用药提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Though sertraline is commonly prescribed in patients with major depressive disorder (MDD), its superiority over placebo is only marginal. This is in part due to the neurobiological heterogeneity of the individuals. Characterizing individual-unique functional architecture of the brain may help better dissect the heterogeneity, thereby defining treatment-predictive signatures to guide personalized medication. In this study, we investigate whether individualized brain functional connectivity (FC) can define more predictable signatures of antidepressant and placebo treatment in MDD. The data used in the present work were collected by the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study. Patients (N = 296) were randomly assigned to antidepressant sertraline or placebo double-blind treatment for 8 weeks. The whole-brain FC networks were constructed from pre-treatment resting-state functional magnetic resonance imaging (rs-fMRI). Then, FC was individualized by removing the common components extracted from the raw baseline FC to train regression-based connectivity predictive models. With individualized FC features, the established prediction models successfully identified signatures that explained 22% variance for the sertraline group and 31% variance for the placebo group in predicting HAMD17 change. Compared with the raw FC-based models, the individualized FC-defined signatures significantly improved the prediction performance, as confirmed by cross-validation. For sertraline treatment, predictive FC metrics were predominantly located in the left middle temporal cortex and right insula. For placebo, predictive FC metrics were primarily located in the bilateral cingulate cortex and left superior temporal cortex. Our findings demonstrated that through the removal of common FC components, individualization of FC metrics enhanced the prediction performance compared to raw FC. Associated with previous MDD clinical studies, our identified predictive biomarkers provided new insights into the neuropathology of antidepressant and placebo treatment.
引用
- Zhao K, Xie H, Fonzo GA, et al. Individualized fMRI connectivity defines signatures of antidepressant and placebo responses in major depression. Mol Psychiatry. 2023. PMID: 36732585. doi:10.1038/s41380-023-01958-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。